Revelation Biosciences, Inc. (REVB) has a negative trailing P/E of -0.9, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 0.7 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -116.54%, forward earnings yield 151.52%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 56/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -97,628.9 | 0.00 | -97,628.86 | 0.00 | - |
| 2020 | -74.8 | 0.00 | 35.73 | 0.00 | - |
| 2021 | -33.6 | -0.27 | -4,048.98 | 0.00 | - |
| 2022 | -4.0 | 0.08 | 40.89 | 0.00 | - |
| 2023 | -342.7 | 3.43 | 6.20 | 0.00 | - |
| 2024 | -1.0 | 0.00 | 3.22 | 0.00 | - |
| 2025 | -2.2 | 0.03 | 2.24 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.42 | $0.00 | $-3.64K | - |
| 2020 | $-188.18 | $0.00 | $-1.63M | - |
| 2021 | $-32.41 | $0.00 | $-11.99M | - |
| 2022 | $-20.11 | $0.00 | $-10.83M | - |
| 2023 | $105.02 | $0.00 | $-120K | - |
| 2024 | $-9.44 | $0.00 | $-15.04M | - |
| 2025 | $-23.95 | $0.00 | $-8.91M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-4.16 | $-5.68 – $-2.62 | $48.97M | $48.97M – $48.97M | 2 |
| 2027 | $-3.30 | $-4.23 – $-2.35 | $2.28M | $2.28M – $2.28M | 2 |
| 2028 | $1.81 | $1.81 – $1.81 | $25.38M | $25.38M – $25.38M | 1 |
| 2029 | $3.91 | $3.91 – $3.91 | $48.1M | $48.1M – $48.1M | 1 |
| 2030 | $8.56 | $8.56 – $8.56 | $107.58M | $107.58M – $107.58M | 1 |
